Pioglitazone
From Pharmacopedia
More actions
Pioglitazone
Actos
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
15-30 mg PO once daily; titrate to 45 mg
Preparations
15, 30, 45 mg tablets
US FDA Max
45 mg/d
Pharmacology
Routes
Oral
Onset
HbA1c effect at 12-16 weeks (slower than other classes)
Duration
24 hours
Half-life
~3-7 hours (parent); 16-24 hours including active metabolites[1]
Bioavailability
High (oral; absorption not affected by food)[1]
Pregnancy
Limited data; switch to insulin where feasible.[citation needed]
Legal status
Purported mechanism
Pioglitazone is a selective agonist of peroxisome proliferator-activated receptor γ (PPAR-γ); the activated receptor remodels transcription of adipocyte differentiation, lipid storage, and insulin-sensitivity genes, lowering insulin resistance with effects on free fatty acid handling, adiponectin secretion, and inflammatory tone.0 Mechanism is insulin-sensitizing rather than insulin-secretagogue, so monotherapy hypoglycemia risk is low. Characteristic adverse effects: fluid retention (HF precipitation), weight gain, distal bone fracture risk (especially in women), and a small bladder cancer signal historically debated; benefit in NASH/MASH and the IRIS trial's stroke recurrence benefit in insulin-resistant non-diabetics keep pioglitazone clinically interesting[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Actos (pioglitazone HCl), Takeda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s055lbl.pdf